Topic Listing for CEPHEID

Abi Northrop Grumman Corporation Accessing Cepheids Full 2008 Results Conference Call
Accessing Cepheids Full 2009 Results Conference Call Accessing Cepheids Q109 Results Conference Call
Accessing Cepheids Q209 Results Conference Call Accessing Cepheids Q308 Results Conference Call
Accessing Cepheids Q309 Results Conference Call Accessing Webcasts
Account Agreement Accounting Tax Implications Compensation Policies
Acquire Companies Products Technologies Face Risks Associated Those Acquisitions
Actigenics Action Respect Securities Other Corporations
Addendum Credit Line Account Application Agreement Adjustments
Adjustments Changes Capitalization Merger Administration
Adopted Pursuant Alternative Financing
Amendment 2000 Employee Stock Purchase Plan Amendment Termination Plan
Amendments Amplification Detection
Analyte Specific Reagents Asrs Andrew Miller
Announces Actions Reduce 2009 Spending Annual Meeting
Annual Report Form 10-k Applied Biosystems
Approval Indemnity Attestation Report Independent Registered Public Accounting Firm
Auction Rate Securities Audit Committee Report
Authorized Signatory Borrower Persons Designated Applicable Ubs Bank Automated Sample Preparation
Available Information Aviso Para Fiador Spanish Translation Required Law
Background Stock Compensation Cepheid Backlog
Base Compensation Base Salary
Become Subject Claims Relating Improper Handling Storage Disposal Benchmarking
Beneficial Ownership Cepheid Stock Beneficial Ownership Reporting Compliance
Benefits Addition Eligible Participate Regular Health Insurance Bonus Biomerieux
Biomerieux Inc Board Directors Meetings Committees
Business Combinations Business Harmed Adverse Economic Conditions Target Markets Reduced
Business Outlook Call
Cannot Successfully Commercialize Products Business Harmed Cash Bonuses
Cash Compensation Paid Board Members Cash Equivalents
Cash Equivalents Investments Cash Equivalents Marketable Securities
Cash Equivalents Marketable Securities Investments Cash Equivalents Short-term Investments
Cash Flow Cash Incentives
Catastrophe Strikes Manufacturing Facilities Unable Manufacture Products Substantial Centers Disease Control Prevention
Cepheid Cepheid Earnings Announcement
Certain Products Fail Obtain Adequate Level Reimbursement Third-party Certain Relationships Related Transactions
Certain Single Source Suppliers Fail Deliver Key Product Certificates Stock
Certification Chief Executive Officer Pursuant Usc 1350 Adopted Chairman Board
Changes Accounting Treatment Stock Options Adversely Affect Results Changes Internal Control Over Financial Reporting
Chief Executive Officer Chief Executive Officer Compensation
Chief Financial Officer Clinical Reagent Business Grows Year-over-year Record 241
Code Code Ethics
Collaboration Profit Sharing Collaborative Agreements Contracts
Collateral Account Features Collateral Description Attachment Ucc National Form Financing Statement
Commitments Contingencies Commitments Contingencies Legal Matters
Committee Meetings Committees Board Directors
Common Stock Compensation Committee Interlocks Insider Participation
Compensation Committee Report Compensation Directors
Compensation Evaluation Processes Criteria Competition
Competitors Potential Develop Superior Products Technologies Competitive Position Compliance New Regulations Governing Public Corporate Governance Reporting
Compliance Regulations Governing Public Corporate Governance Reporting Complex Components Compensation
Comprehensive Income Loss Comprehensive Loss
Concentration Credit Risk Conduct Business
Conduct Business Action Without Meeting Consent Independent Registered Public Accounting Firm
Contingencies Contract Revenue
Contract Revenues Contractual Cash Bonus Senior Vice President Chief Financial
Contractual Obligations Controls Procedures
Corporate Seal Corporate Transactions
Cost Product Sales Costs Operating Expenses
Credit Line Checks Critical Accounting Policies Estimates Assumptions
Current Uncertainty Global Economic Conditions Makes Particularly Difficult Definitions
Delegation Authority Derivative Instruments Hedging Activities
Designation Beneficiary Details Compensation Paid Named Executive Officers
Determining Fair Value Sfas 123 Determining Fair Value Sfas 123r
Direct Selling Efforts Products Fail Business Expansion Plans Director Attendance Annual Meeting
Director Summary Compensation Table Directors Nominees
Disposable Smartcycler Reaction Tubes Distribution Collaboration Arrangements
Distributor Relationships Not Successful Ability Market Sell Products Documents Incorporated Reference
Eighth Consecutive Growth Clinical Reagents 2008 Election Directors
Election Inspectors Election Term
Election Term Office Vacancies Eligibility
Eligibility 162 Employee Benefit Plan
Employee Stock Purchase Plan Employees
Enrollment Espp Enter Collaborations Parties Not Result Development Commercially Viable
Equipment Building Financing Equity Compensation Paid Board Members
Equity Compensation Plan Information Equity-based Long-term Incentives
Erisa Information Estimates
Evaluation Criteria Evaluation Disclosure Controls Procedures
Evaluation Process Exact Name Registrant Specified Charter
Exchange Act Executive
Executive Officers Executive Officers Registrant
Executive Vice President Chief Medical Technology Officer Executive Vice President Chief Medical Technology Officer Compensation
Executive Vice President Chief Operating Officer Executive Vice President Operations Compensation
Exhibits Expect Operating Results Fluctuate Significantly Failure Meet Financial
Expect Operating Results Fluctuate Significantly Particularly Given Adverse Expense Patent-related Matter
Explanatory Face Risks Associated Acquisitions Companies Products Technologies Business
Facility Lease Facility Leases
Facsimile Signatures Fail Maintain Protect Intellectual Property Rights Competitors Technology
Fail Retain Key Members Staff Ability Conduct Expand Fair Value
Fair Value Financial Instruments Financial Condition Outlook
Financial Instruments Financial Statements
Financial Statements Exhibits Firm
Fixed Rate Advance Prime Credit Lines Food Drug Administration Issued Draft Interpretation Regulations Governing
Food Drug Administration Issued Final Interpretation Regulations Governing Foreign Currency Hedging
Form 10-k Form 10-q
Former Name Address Changed Since Last Report Forward Looking Statements
Forward-looking Statements Foundation Innovative New Diagnostics
Full Earnings Announcement Conference Call Full Revenue Results
Funds Associated Certain Auction Rate Securities Not Accessible Gain Legal Settlement
General General Administrative Expenses
Generally Genexpert
Genexpert Anthrax Cartridge Genexpert Module
Genexpert System Momentum Drives Year-over-year Growth Core Clinical Government Regulation
Grant Government Sponsored Research Revenue Grants Government Sponsored Research Revenue
Grants Plan-based Awards Table Headings
Held 2007 Held 2009
Impairment Intangible Assets Impairment Intangible Assets Goodwill
Important Notice Interest Rates Payments Important Notice Regarding Availability Proxy Materials
In-process Research Development Incentive Stock Options
Income Taxes Indemnification Employees Agents Corporation
Index Inducement Stock Option Award
Industry Background Infectio Diagnostic Inc Geneohm Sciences
Infectio Diagnostics Inc Inspection Records Properties
Insurance Intangible Assets
Intangible Assets Goodwill Intellectual Property
Interest International Operations Subject Additional Risks Costs
Inventory Inventory Reserve Warranty Accrual
Inventory Warranty Provisions Investments Marketable Debt Securities Subject Risks Cause Losses
Itemization Amount Financed Disbursement Instructions Revolver John Sluis
Key Employee Incentive Plan Key Terms
Lawrence Livermore National Laboratory Leases Commitments Contingencies
Legal Matters Legal Proceedings
Licenses Strategic Relationships Life Sciences Industry Highly Competitive Subject Rapid Technological
Limit Limitations Shares Purchased
Liquidity Capital Resources List
List Subsidiaries Lost Stolen Destroyed Certificates
Managements Annual Report Internal Control Over Financial Reporting Managements Report Internal Control Over Financial Reporting
Manner Exercise Manufacturing
Margin Calls Interest Payments Marketable Securities
Material Terms Employment Agreements Meeting Without Regular Call Notice
Might Require Additional Capital Respond Business Challenges Acquisitions Might Require Additional Capital Support Business Growth Such
Nature Some Products Also Subject Export Control Regulation Need Initiate Lawsuits Protect Enforce Patents Expensive Lose
Net Loss Per Share New Plan Benefits
Newly Created Directorships Vacancies Non Exclusivity Rights
Non-employee Director Stock Options Non-employee Directors Stock Option Plan
Non-gaap Measures Non-plan Stock Option Exercise Agreement
Non-qualified Stock Options Nonassignability
Not Achieve Profitability Notes Payable
Notice Notice Annual Meeting Shareholders Held 2008
Notice Borrower Advances Agreement Demand Loans Collected Lender Notice Borrower Not Sign Agreement Before Read Provides
Notice Co-signer Traduccion Ingles Requiere Por Ley Notice Joint Borrower Signature Agreement Means Equally Liable
Notice Meetings Notices
Number Number 000-0030755
Number 000-30755 Off-balance-sheet Arrangements
Offering Periods Purchase Omnimix
Operating Results Fluctuate Significantly Particularly Given Adverse Worldwide Operating Results Materially Affected Unanticipated Changes Tax Provisions
Operational Overview Option Exercises Stock Awards
Organization Organization Business
Organization Summary Significant Accounting Policies Other Benefits
Other Business Other Income Expense Net
Other Income Net Other Officers
Other Revenue Overview
Overview Philosophy Part
Part Ii-other Information Part Other Information
Participation Usps Bds Program Not Result Predictable Contracts Participation Usps Bds Program Not Result Predictable Revenues
Participation Usps Biohazard Detection System Program Other Similar Patent License Agreements
Patent License Amortization Payment Purchase Price Changes Payroll Deductions Issuance Shares
Payment Purchase Price Payroll Deductions Payments
Performance Shares Plan History
Please Indicate Compliance Status Circling Yes Complies Column Powers
Presentation Todays Morgan Conference Available Website President
Price Range Common Stock Principal Accountant Fees Services
Principles Consolidation Product Liability Lawsuits Successfully Brought Against Face Reduced
Product Sales Products
Products Fail Obtain Adequate Level Reimbursement Third-party Payers Products Infringe Intellectual Property Rights Others Face Costly
Products Not Perform Expected Reliability Technology Based Questioned Property Equipment
Proxies Voting Purchase Price
Purchase Price Allocation Purchase Stock Grant Options
Purchased Intangible Assets Purpose
Purpose Eip Pursuant 302
Quantitative Qualitative Disclosures Market Risk Quantitative Qualitative Disclosures Market Risks
Quorum Quorum Abstentions Broker Non-votes
Quorum Required Vote Ratification Appointment Independent Auditors
Ratification Appointment Independent Registered Public Accounting Firm Realizability Long-lived Assets
Recent Accounting Pronouncements Recent Deterioration Current Uncertainty Global Economic Conditions Makes
Recitals Reclassification
Reclassifications Record Date
Reformatted Certain Products Affected Food Drug Administration Final Registrants Telephone Number Including Area Code
Regulations Regulatory Approval Process Expensive Time-consuming Uncertain Prevent Obtaining
Related Person Transaction Policy Reliance Books Reports Records
Rely Licenses Key Technology Parties Require Additional New Rely Relationships Collaborative Partners Other Parties Development Supply
Remedies Removal
Report Independent Registered Public Accounting Firm Representations Warranties Covenants Loan Parties
Required Vote Research Development
Research Development Expenses Reserved Shares
Resignation Restatement Consolidated Financial Statements-patent License Amortization
Restricted Cash Restricted Stock
Restricted Stock Units Restructuring
Restructuring Charge Revenue Guidance
Revenue Recognition Revenues
Revocability Proxies Revolving Line Credit
Right Advancement Expenses Right Indemnification
Right Indemnitee Bring Suit Role Compensation Committee
Role Independent Compensation Consultant Salary Bonus Proportion Total Compensation
Sales Sales Channels
Sales Cycle Lengthy Cause Variability Unpredictability Operating Results Sales Cycle Particularly Life Sciences Market Lengthy Cause
Sales Marketing Expenses Sangtec
Sarbanes-oxley Act 2002 Schedule
Schedule Exceptions Schedule Ubs Bank Usa Credit Line Agreement
Schedule Valuation Qualifying Accounts Schedules
Secretary Securities Exchange Act 1934
Securities Registered Pursuant Act Security Ownership Certain Beneficial Owners Management
Segment Significant Concentrations Selling General Administrative Expenses
Senior Vice President Chief Financial Officer Senior Vice President Worldwide Commercial Operations
Senior Vice President Worldwide Commercial Operations Compensation Severance Agreements
Shareholder Communications Shareholder Proposals
Short-term Investments Subject Risks Cause Losses Affect Liquidity Signatures
Signing Below Borrower Understands Acknowledges Agrees Single Source Suppliers Fail Deliver Key Product Components
Smartcycler Solution
Special Limitations Special Meetings Notice
Spousal Consent Stock Appreciation Rights
Stock Based Compensation Stock List
Stock Options Equity Awards Stock Price Highly Volatile Investing Involves High Degree
Stock Price Performance Stock Price Performance Graph
Stock-based Compensation Strategy
Stretton Subject Third-party Claims Require Additional Licenses Products Face
Subject Third-party Claims Require Additional Licenses Products Such Submission Matters Vote Security Holders
Summary Executive Compensation Table Contents
Target Levels Performance-based Awards Tax Consequences
Termination Termination Interruption Employment
Terms Advances Terms Applicable Restricted Stock Awards Unit Performance Shares
Terms Applicable Stock Options Appreciation Rights Test Menu Expansion Drives Full Clinical Business Growth
Time Periods Time Place Meetings Telephone
Title Class Total Return Stockholders
Transferability Transfers Stock
Unable Manufacture Products Sufficient Quantities Timely Manner Operating Undersigned Represents Warrants Foregoing True Complete Correct Information
United States United States Government Certain Rights Disclose Some Intellectual
Usa Patriot Act Notice Customer Identification Vesting Exercise Period
Vice President Worldwide Commercial Operations Vote Important
Voting Solicitation Waiver Notice
Waivers Warrants
Warranty Accrual Warranty Provision
Warranty Reserve Withdrawal
Year-over-year Growth Clinical Reagents Highlights Strong Adoption Genexpert 
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki